MULTIPLE DRUG RESISTANCE IN HUMAN SOLID TUMORS

人类实体瘤的多重耐药性

• 批准号: 3187516
• 负责人: Awtar Ganju-Krishan
• 金额: $ 16.97万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-05-01 至 1992-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3187516
• 关键词: drug resistance; neoplasm /cancer; neoplasm /cancer chemotherapy

Multiple Drug Resistance (MDR) is a major reason for failure of cancer chemotherapy. Earlier studies on murine cell lines have identified certain biochemical mechanisms (e.g. rapid drug efflux) responsible for MDR. Cellular markers such as cell surface glycoproteins are often associated with MDR. Our knowledge about MDR in solid tumors is limited and it is important to study drug resistance in human soild tumors, as more often than not, MDR results in treatment failure. In the present study, we propose to study MDR in human solid tumor cells isolated from ascites and pleural fluid of patients and from xenografts earlier established. We will use our laser excitation method to sort and study tumor cells on the basis of their anthracycline fluorescence content. Drug transport characteristics will be studied with or without exposure to drug efflux blockers. Biochemical mechanisms responsible for MDR as well as well-known markers of MDR will be studied. It is hoped that the studies proposed will provide insights into mechanisms involved in MDR of human solid tumors.

多药耐药(MDR)是癌症失败的主要原因 化疗。早期对小鼠细胞系的研究已经发现了某些 导致多药耐药的生化机制(如快速药物外排)。 细胞标志物，如细胞表面糖蛋白，通常与 使用MDR。我们对实体肿瘤多药耐药的了解是有限的，而且 重要的是研究人类实体肿瘤的耐药性，因为 不，多药耐药会导致治疗失败。 在本研究中，我们建议研究人实体瘤细胞的多药耐药。 从患者腹水和胸水及异种移植物中分离出 更早建立的。我们将使用我们的激光激发方法来分类和 根据肿瘤细胞的蒽环类荧光含量来研究肿瘤细胞。 药物转运特性将在接触或不接触的情况下进行研究 药物外流阻滞剂。多药耐药的生化机制以及 将对MDR的知名标记进行研究。 希望拟议的研究将提供对机制的洞察 参与人实体肿瘤的多药耐药。